Duramed (DRMD) Synthetic Estrogen Product Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: harkenman who wrote (1309)	6/11/1999 8:11:00 AM
From: vestor	Read Replies (1) of 1837

We think that in the short term that $24 to $26. per share is attainable this summer given B/C pill approval and fair to good Censetin market penetration.... We think the advertising pgm set to begin in July will lend to share price appreciation...... We see a $35 to $40. per share scenario by years end should there be progress in the Cenestin combination drug application..... We see the the request to treat Osteperosis with Censtin approval as only a matter of time and have very strong feelings that the Cenestin/Progesterin application will also be approved. We anticipate that by years end sales of Censetin will rapidly grow and take considerable market share from Premarin..... Even if the drug group is not in favor we think the fundamentals and potentials are significant enough to drive the share price to the above stated targets..... We are not factoring any takeover driven share price appreciation and use a conservative 5 % Cenestin market penetration. We agree that the B/C pill should generate about $150. mil a year especially if DRMD is able to take advantage of the recently opened Japanese market...... The PIC point of view.....

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next